This clinical trial is focused on studying the effects of chemotherapy in patients with metastatic colorectal cancer, which is a type of cancer that has spread from the colon or rectum to other parts of the body. The study will use several medications, including irinotecan hydrochloride trihydrate, fluorouracil, oxaliplatin, capecitabine, disodium folinate, and calcium folinate pentahydrate. These medications are commonly used in cancer treatment and will be administered either through infusion, which is a method of delivering medication directly into the bloodstream, or orally in the form of tablets.
The purpose of this study is to compare the effectiveness of additional chemotherapy after the surgical removal or destruction of cancerous growths, known as metastases, with a structured follow-up approach. Participants in the study will receive treatment over a period of up to 24 months. During this time, they will be monitored regularly to assess their health and the progression of the disease. The study aims to determine whether the additional chemotherapy can help improve outcomes for patients by preventing the cancer from returning or spreading further.
Participants will be randomly assigned to different treatment groups, and some may receive a placebo. The study is designed to be open, meaning both the participants and the researchers will know which treatment is being administered. The main goal is to evaluate the time it takes for the disease to progress or for the patient to pass away, which is referred to as progression-free survival. This information will help researchers understand the potential benefits of post-surgery chemotherapy in managing metastatic colorectal cancer.
Germany 
